GlaxoSmithKline plc and the University of Oxford announced a major five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine. The new Institute, which will be based at the University of Oxford, aims to improve the success and speed of research and development of new medicines, building on insights from human genetics and using advanced technologies such as functional genomics and machine learning.
GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease
December 3, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022